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Abstract
Background: Pain is a frequent symptom in aquaporin-4-immunoglobulin-G-positive neuromyelitis
optica spectrum disorders (AQP4-IgG-pos. NMOSD). Data on pain in myelin-oligodendrocyte-
glycoprotein-immunoglobulin-G autoimmunity with a clinical NMOSD phenotype (MOG-IgG-pos.
NMOSD) are scarce.
Objective: The objective of this paper is to investigate pain in MOG-IgG-pos. NMOSD, AQP4-IgG-pos.
NMOSD and NMOSD without AQP4/MOG-IgG detection (AQP4/MOG-IgG-neg. NMOSD).
Methods: Forty-nine MOG-IgG-pos. (n¼ 14), AQP4-IgG-pos. (n¼ 29) and AQP4/MOG-IgG-neg.
(n¼ 6) NMOSD patients were included in this cross-sectional baseline analysis from an ongoing obser-
vational study. We identified spinal cord lesions on magnetic resonance imaging, assessed pain by the
painDETECT and McGill Pain questionnaires, quality of life by Short Form Health Survey, and depres-
sion by Beck Depression Inventory.
Results: Twelve MOG-IgG-pos. NMOSD patients (86%), 24 AQP4-IgG-pos. NMOSD patients (83%),
and all AQP4/MOG-IgG-neg. NMOSD patients (100%) suffered from pain. MOG-IgG-pos. NMOSD
patients had mostly neuropathic pain and headache; AQP4-IgG-pos. and AQP4/MOG-IgG-neg.
NMOSD patients had mostly neuropathic pain. A history of myelitis was less frequent in MOG-IgG-
pos. NMOSD than in AQP4-IgG-pos. NMOSD patients. Pain influenced quality of life in all patients.
Thirty-six percent of patients with pain received pain medication; none of them were free of pain.
Conclusions: Pain is a frequent symptom of patients with MOG-IgG-pos. NMOSD and is as important
as in AQP4-IgG-pos. and AQP4/MOG-IgG-neg. NMOSD. Despite its impact on quality of life, pain is
insufficiently alleviated by medication.
Keywords: Aquaporin 4 (AQP4), myelin oligodendrocyte glycoprotein antibody (MOG), neuromyelitis
optica (NMO) spectrum disease (NMOSD), pain
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Introduction
Pain is one of the most frequent comorbidities of
neurologic diseases and severely reduces the quality
of life (QoL) of affected patients. In the management
of patients with neuroinflammatory diseases, the
appropriate treatment of pain is a difficult challenge.
Neuromyelitis optica spectrum disorders (NMOSD)
are inflammatory autoimmune diseases of the central
nervous system (CNS) associated with
immunoglobulin G antibodies (IgG) to the astrocytic
water channel aquaporin-4 (AQP4), to myelin oligo-
dendrocyte glycoprotein (MOG) or in some cases
without antibody proof.1,2 Currently, it is unclear
whether MOG-IgG-positive NMOSD (MOG-IgG-
pos. NMOSD) is a disease entity of its own, defined
by the presence of anti-MOG-IgG and a clinical phe-
notype similar to AQP4-IgG-positive NMOSD
(AQP4-IgG-pos. NMOSD). Consequently, some
authors recognize both diseases as separate disease
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entities based on different cellular pathologies,3
while others describe them as different forms of a
larger disease spectrum, usually under the NMOSD
umbrella, based on a similar clinical phenotype char-
acterized by relapsing optic neuritis and/or extensive
transverse myelitis leading to blindness, weakness,
numbness, cognitive impairment, and pain.4,5
Systematic studies of pain syndromes associated
with NMOSD are relatively scarce and have so far
been limited to AQP4-IgG-positive or AQP4-IgG-
negative NMOSD.6–10 Here, we systematically
study pain syndromes of patients suffering from
MOG-IgG-pos. NMOSD, contribute to the literature
on pain syndromes of patients with AQP4-IgG-pos.
and AQP4/MOG-IgG-neg. NMOSD, and provide a
comparison of pain syndromes and QoL aspects in
MOG-IgG-pos. and AQP4-IgG-pos. NMOSD.
Methods
Ethics, study protocol and patient sample
Data are derived from the baseline visit of an ongo-
ing observational study that is following patients
with AQP4-IgG-pos. NMOSD and related disorders.
The study was approved by the ethics committee of
the Charite´–Universit€atsmedizin Berlin, Germany
(EA1/041/14) and conducted according to the 1964
Declaration of Helsinki in its currently applicable
version. All participants provided written informed
consent prior to inclusion.
Inclusion criteria for this analysis were diagnosis of
NMOSD according to the international consensus
diagnostic criteria for NMOSD 20151 or positive
proof of anti-MOG-IgG associated with a demyelin-
ating disease of the CNS with a clinical phenotype
equivalent to NMOSD diagnosis criteria in patients
over 18 years of age.2 Anti-MOG-IgG was detected
by a live cell-based assay using HEK293A cells
transfected with full-length human MOG and was
confirmed by means of a commercial fixed-cell
based assay with HEK293 cells transfected with
full-length human MOG (Euroimmun, Lu¨beck,
Germany).2,4 We treated MOG-IgG positivity as
equivalent to positive AQP4-IgG for fulfilling the
diagnostic criteria.
At the time of screening, our database contained 53
baseline visits. Forty-nine patients were included in
the analysis. Of these, 14 patients suffered from
MOG-IgG-pos. NMOSD and 29 patients from
AQP4-IgG-pos. NMOSD.1 Six patients fulfilled the
2015 International Panel for NMO Diagnosis criteria
for NMOSD and were negative for anti-MOG-IgG
and anti-AQP4-IgG. Three patients were not includ-
ed in the analysis because of a diagnosis of antibody-
negative isolated longitudinally extensive transverse
myelitis without fulfilling NMOSD diagnostic crite-
ria or positive MOG-IgG testing. One patient was
excluded because of incomplete pain assessment.
The resulting female-to-male ratio of 2.5:1 in the
MOG-IgG-pos. and of 9:1 in the AQP4-IgG-pos.
NMOSD patients corresponds to previous data in
the literature.1,4,11,12 Demographic data, Expanded
Disability Status Scale (EDSS), and health-related
quality of life (hr-QoL) assessment scores were sim-
ilar between MOG-IgG-pos. and AQP4-IgG-pos.
NMOSD patients (Table 1).
Clinical data
We recorded immunotherapies and pain medication
including nonsteroidal anti-inflammatory drugs,
anticonvulsants, tricyclic antidepressants, atypical
antidepressants, selective serotonin norepinephrine
reuptake inhibitors, selective serotonin reuptake
inhibitors and muscle relaxants. Every patient had
a medical interview by a trained neurologist about
clinical history and underwent a neurological exam-
ination determining the EDSS.
All scales used in this study are established measure-
ments for pain7,13,14 and hr-QoL6,7,9,13,15 both in
multiple sclerosis and in NMOSD.
Pain assessment
Pain was recorded whenever a patient reported via
the painDETECT questionnaire (PDQ) either current
pain or pain within the previous four weeks.
Neuropathic pain is pain caused by a lesion or dis-
ease affecting the somatosensory system.16 We clas-
sified pain as neuropathic if sensory signs
corresponding to the affected nervous structure
were examined, and if the magnetic resonance imag-
ing (MRI) confirmed a corresponding CNS lesion.16
We administered the PDQ to ask about pain locali-
zation and current and previous pain. The PDQ sup-
ports the discrimination of neuropathic and
nociceptive pain by seven questions about pain qual-
ity. Each quality is rated from 0 to 5 so a maximum
subscale score of 35 can be reached. A PDQ-score of
12 or higher is indicative of neuropathic pain,14,17
but was not used as a deciding diagnostic criterion.
Similar to previous findings,18 the sensitivity of the
PDQ compared to the clinical diagnosis of neuro-
pathic pain was only 70%.
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In the McGill Pain Questionnaire (MGQ), patients
describe their pain experience with up to 20 words
from a list of 78 words, categorized as sensory-
discriminative to describe the sense of intensity,
location and duration of pain, as motivational-
affective to describe unpleasantness, and as
cognitive-evaluative to describe cognitions such as
appraisal. The chosen words map onto a rating index
ranging from 0 to 78 with higher values meaning
worse pain.19
hr-QoL
We measured hr-QoL with the Short Form 36 Health
Survey (SF-36). A Physical and a Mental
Component Summary (PCS/MCS) were calculated
using norm-based attaining values from 0 (worst)
to 100 (best).20
Self-reported effect of general health and fatigue
was acquired by visual analog scales (VAS) asking
in German, “How strong is your fatigue/impairment
of general health?” labeled with “no fatigue/
impairment” as the starting point and “unbearable
fatigue/impairment” as the end point. The different
positions are related to numbers between 0 (best)
and 100 (worst).21
To evaluate depressive symptoms, we administered
the Beck Depression Inventory (BDI-II). It contains
21 questions with a score from 0 (best) to 63 (worst)
(0–9: nondepressive affect; 10–19: minimal mood
disturbance; 20–29:moderate depression; 30 and
above: severe depression).22
MRI
MRI was performed with a Siemens 3-Tesla
Magnetom Trio scanner (Erlangen, Germany).
A neuroradiologist (M.S.) reviewed scans of the
brain (three-dimensional (3D) fluid-attenuated inver-
sion recovery, 1 mm isotropic resolution, repetition
time (TR)/echo time (TE)/inversion time (TI)¼
6000/388/2100 ms) and spinal cord (T2-weighted
sagittal, 3 mm slice thickness, TR/TE¼ 3500/101
ms) to detect residual lesions to confirm or reject
the diagnosis of neuropathic pain.
Statistical analysis
We carried out all statistical analyses using IBM
SPSS Statistics version 22.0 software (IBM,
Armonk, NY, USA). Demographic and clinical char-
acteristics are shown as means plus standard devia-
tion and as range or counts. We performed the
Mann-Whitney U test to compare ordinal data, the
Fisher exact test to compare binary data between
MOG-IgG-pos. and AQP4-IgG-pos. NMOSD
patients, and the Pearson correlation test to explore
the relationships between the dependent measure of
pain intensity and the independent variables of SF-
36, VAS and BDI-II. All tests were two tailed and
significance was set as p< 0.05. Data derived from
AQP4/MOG-IgG-neg. NMOSD patients are descrip-
tively listed because of the low sample size. All sta-
tistical analyses have explorative character and
should be interpreted as statistical tendency.
Results
MOG-IgG-pos. NMOSD patients suffered consider-
ably from pain. Pain frequency, intensity, pain type,
pain localization and frequency of pain treatment
were comparable to AQP4-IgG-pos. NMOSD
patients (Tables 2 and 3). Twelve out of 14 MOG-
IgG-pos. NMOSD patients (86%) indicated via the
PDQ that they suffer from pain. Average pain inten-
sity was mild; one patient (7%) suffered from severe
pain. According to medical interview, clinical exam-
ination, and MRI, five MOG-IgG-pos. NMOSD
patients suffered from neuropathic pain (41.6%),
whereas only three patients had a PDQ score >12.
Six MOG-IgG-pos. NMOSD patients reported
mainly headache/neck pain (50%). Pain types com-
prised retrobulbar pain (n¼ 2), tension headache in
association with recurrent optic neuritis (n¼ 1),
occipital neuralgia (n¼ 1) and cervicogenic head-
ache (n¼ 2). Three patients additionally suffered
from migraine, which was aggravated in two of
them in the context of MOG-IgG-pos. NMOSD.
All MOG-IgG-pos. NMOSD patients who received
pain medication reported pain and tended to have
stronger pain than those without pain-
relieving treatment.
Similar to the pain frequency among MOG-IgG-pos.
NMOSD patients, 24 out of 29 AQP4-IgG-pos.
NMOSD patients (83%) suffered from pain. The
average pain intensity was mild. However, four
AQP4-IgG-pos. NMOSD patients (14%) suffered
from severe pain. Nineteen AQP4-IgG-pos.
NMOSD patients were diagnosed with neuropathic
pain (82.6%). Among these, 17 patients had a PDQ-
score indicating probable neuropathic pain. Five
AQP4-IgG-pos. NMOSD patients suffered mainly
from headache/neck pain (21.7%). Headache types
comprised tension headache (n¼ 3) that occurred in
two patients as a primary symptom of the NMOSD,
occipital neuralgia (n¼ 1) and cervicogenic head-
ache (n¼ 1). Eight AQP4-IgG-pos. NMOSD
patients with pain who received pain medication
still reported pain. Present pain intensity
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(p¼ 0.025) and maximal pain intensity in the previ-
ous four weeks (p¼ 0.041) were higher in patients
with pain medication than in those without. Detailed
results of the PDQ are shown in Supplementary
Table 1. Table 3 provides details on pain intensity
and hr-QoL subject to pain medication.
Pain intensity had a substantial impact on patients’
well-being. Present pain intensity was correlated
with higher depression scores in MOG-IgG-pos.
NMOSD patients (p¼ 0.001) and with emotional
affect (measured with MCS) both in MOG-IgG-
pos. NMOSD (p¼ 0.047) and in AQP4-IgG-pos.
NMOSD patients (p¼ 0.031). With growing pain
intensity, the latter showed moreover a stronger
effect on general health (p< 0.001), PCS
(p¼ 0.008) and fatigue (p< 0.001) (Supplementary
Table 1). Thus, MOG-IgG-pos. and AQP4-IgG-pos.
NMOSD patients were similar with respect to differ-
ent quantitative and qualitative aspects of pain as
well as to related aspects of their hr-QoL.
To describe their pain experience, MOG-IgG-pos.
and AQP4-IgG-pos. NMOSD patients chose differ-
ent words within the MGQ, but the number of
chosen words, and the pain intensity in all catego-
ries, were similar. The cognitive-evaluative compo-
nent was the most affected. MOG-IgG-pos. NMOSD
patients described their pain experience in the MGQ
mainly by the sensory-discriminative word
“throbbing” (50%), by the motivational-affective
word “punishing” (62.5%) and by the cognitive-
evaluative word “annoying” (50%). AQP4-IgG-
pos. NMOSD patients described their pain quality
mainly by the sensory-discriminative words
“flashing” (55.6%), “pricking” (61.11%) and
“tingling” (62.5%). A detailed evaluation of MGQ
is provided in Supplementary Table 2.
MOG-IgG-pos. and AQP4-IgG-pos. NMOSD
patients showed a similar effect on their hr-QoL.
As expected, all patient groups showed impaired
mental and physical function in the SF-36 survey
(Table 1). There was no difference between MOG-
IgG-pos. and AQP4-IgG-pos. NMOSD patients
(PCS: p¼ 0.687; MCS: p¼ 0.430). Both groups
indicated a clear effect on general health and fatigue
(Tables 1 and 2). MOG-IgG-pos. NMOSD patients
with pain-relieving treatment reported a higher
impairment of general health than those without
pain medication (p¼ 0.048; Table 3). Both MOG-
IgG-pos. NMOSD patients without pain did not par-
ticipate in the VAS, while one of them also did not
participate in the SF-36. MOG-IgG-pos. NMOSD
patients compared to AQP4-IgG-pos. NMOSD
patients with pain had similar depression scores
(p> 0.999). Five MOG-IgG-pos. NMOSD patients
(36%) and 12 AQP4-IgG-pos. NMOSD patients
(42%) suffered from mild or moderate depression
according to the BDI-II (Table 1). MOG-IgG-pos.
NMOSD patients with pain had higher depression
scores than those without pain (p¼ 0.022). Table 2
displays the BDI-II results in patients with and with-
out pain.
During assessment, all patients were stable; none of
them had an acute relapse. The different clinical
phenotypes were the following: Both of the MOG-
IgG-pos. NMOSD patients without pain and two
MOG-IgG-pos. NMOSD patients with pain had a
history of recurrent myelitis and optic neuritis. Six
MOG-IgG-pos. NMOSD patients with pain had a
history of recurrent optic neuritis without history
of myelitis, three MOG-IgG-pos. NMOSD patients
with pain had a history of one-time (n¼ 2) or recur-
rent (n¼ 1) myelitis without history of optic neuritis.
Of the latter one patient additionally had a history of
encephalitis and one patient a history of brainstem
syndrome. One MOG-IgG-pos. NMOSD patient
with pain had a clinical presentation of one episode
of atypical facial pain and one episode of crani-
al allodynia.
Twelve AQP4-IgG-pos. NMOSD patients with pain
had a clinical history of recurrent myelitis and optic
neuritis. Three of them additionally had a history of
brainstem syndrome. Two AQP4-IgG-pos. NMOSD
patients with pain had a history of recurrent (n¼ 2)
optic neuritis without history of myelitis, 10 AQP4-
IgG-pos. NMOSD patients with pain had a history of
one-time (n¼ 1) or recurrent (n¼ 9) myelitis with-
out history of optic neuritis. One of them had an
episode of area postrema syndrome and one of
them had a history of brainstem syndrome.
Five AQP4-IgG-pos. NMOSD patients without pain
had a clinical history of recurrent myelitis and optic
neuritis (n¼ 3) or myelitis without history of optic
neuritis (n¼ 2).
Three AQP4/MOG-IgG-neg. NMOSD patients had a
history of recurrent myelitis and optic neuritis. Two
AQP4/MOG-IgG-neg. NMOSD patients had a histo-
ry of one-time optic neuritis without history of mye-
litis and one AQP4/MOG-IgG-neg. NMOSD patient
had a history of myelitis and area post-
rema syndrome.
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A clinical history of myelitis occurred less frequent-
ly in MOG-IgG-pos. NMOSD patients than in
AQP4-IgG-pos. NMOSD patients (p¼ 0.009). All
patients with neuropathic pain showed residual
spinal cord lesions, whereas other pain types
occurred independently from former myelitis
attacks. The respective pain types and their
relationships to myelitis attacks are illustrated in
Figures 1 and 2.
Current immunomodulatory treatment is listed in
Table 1. Four MOG-IgG-pos. NMOSD patients
(33%) and nine AQP4-IgG-pos. NMOSD patients
(37.5%) had a pain treatment, whereas the majority
Figure 1. Flowchart illustrating current pain conditions in MOG-IgG-pos. NMOSD patients with and without a history of
myelitis. n: number of patients; MOG-IgG-pos.: myelin-oligodendrocyte-glycoprotein-immunoglobulin-G-positive;
NMOSD: neuromyelitis optica spectrum disorder. *Others: connective tissue disease, arthralgia of unknown
origin, vasculitis.
Figure 2. Flowchart of current pain conditions in AQP4-IgG-pos. NMOSD patients with and without a history of
myelitis. AQP4-IgG-pos.: aquaporin-4-immunoglobulin-G-positive; n: number of patients; NMOSD: neuromyelitis optica
spectrum disorder. *Others: connective tissue disease, arthralgia of unknown origin, vasculitis.
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of the patients with pain did not have any pain med-
ication. All patients undergoing pain treatment still
suffered from pain. Table 2 provides a list of the
different pain medication classes.
Discussion
MOG-IgG-pos. NMOSD patients suffer from pain at
a frequency comparable to AQP4-IgG-pos. NMOSD
patients. The high prevalence of pain in more than
80% of AQP4-IgG-pos. NMOSD is consistent with
previous findings.6,7,9
Frequent pain syndromes in NMOSD include neuro-
pathic pain, spasticity-associated pain, musculoskel-
etal pain and headache.10,23,24 These pain syndromes
were equally present in our cohort of MOG-IgG-pos.
NMOSD patients. Moreover, we included patients
with pain due to coexisting autoimmune-modulated
diseases such as connective tissue disease and vas-
culitis as they may jointly emerge with and may be
causally linked to NMOSD.1,4
Different dominant pain qualities between the
groups might be generated by different underlying
pathophysiological mechanisms in MOG-IgG-pos.
and AQP4-IgG-pos. NMOSD.
Under healthy conditions the neuropeptide nerve
growth factor (NGF) has a high affinity to tropomy-
osin receptor kinase A (TrkA). TrkA is expressed on
unmyelinated nociceptive axons of the spinal cord
and regulates synaptic strength and plasticity of sen-
sory neurons.25 NGF has a high affinity to bind
MOG, thus loss of MOG by antibody-mediated
destruction in MOG-IgG-pos. NMOSD may cause
abundant NGF-concentrations in the CNS. This
might lead to aberrant sprouting of unmyelinated
nociceptive fibers in the posterolateral tract of the
spinal cord,26 causing chronic neuropathic pain.
Depending on the level of the lesion, this process
could lead to occipital neuralgia or to more distal
neuropathic pain syndromes.
Furthermore, the brainstem is involved in up to one-
third of MOG-IgG-pos. NMOSD patients.27 The
brainstem is a critical region in the pathophysiology
of migraine and trigeminal neuralgia.28,29
Cervicogenic headache can result from inflammato-
ry lesions in the superior cervical spine leading to
musculoskeletal dysfunction.24
In AQP4-IgG-pos. NMOSD the high frequency of
spinal cord lesions might be a risk factor for neuro-
pathic pain.8,10 In line with recent data by Jarius
et al.,2 we show that APQ4-IgG-pos. NMOSD
patients had a higher incidence of clinical myelitis
compared to MOG-IgG-pos. NMOSD patients.
Under healthy conditions AQP4 is coexpressed with
excitatory amino acid transporter 2. Loss of AQP4 in
NMOSD may lead to an excessive accumulation of
glutamate in the extracellular space, interrupting the
glutamine-glutamate-GABA axis. This may disrupt
the balance between excitation and inhibition in
nociceptive pathways23 and lead to neuropathic
pain in AQP4-IgG-pos. NMOSD.
Whereas MOG-IgG-pos. NMOSD patients charac-
terized their pain experience mainly as throbbing,
punishing and annoying, AQP4-IgG-pos. NMOSD
patients described it as flashing, pricking and
tingling. The more affective words used by
MOG-IgG-pos. NMOSD patients might reflect the
important influence of pain on their state of mind.
MOG-IgG-pos. NMOSD patients with pain also
showed a stronger impairment by depression than
those without pain, as well as a positive correlation
between pain intensity and depression grade, indicat-
ing a possible interaction of pain and mood
disorders. Both symptoms are known to make the
emergence and exacerbation of the other symptom
more likely.30 Furthermore, differences in descrip-
tive words could be related to the more common
diagnosis of headaches in the MOG-IgG-pos.
NMOSD patients. To our knowledge, however, a
predominance of certain words to describe headache
compared to other pain conditions is not provided in
the literature. All patients showed a clear impair-
ment of general health and strong restrictions
caused by fatigue.31 MOG-IgG-pos. NMOSD
patients with pain reported a higher impairment by
fatigue than those without pain. This may be a neu-
ropsychological effect whereby chronic pain could
exhaust the patient and lead to fatigue. It could also
be caused by a biochemical process, whereby
increased levels of cytokines present in neuroimmu-
nological diseases32 may contribute to the develop-
ment of fatigue33,34 and pain.23 In addition, deep
gray matter pathology, cortical atrophy and axonal
damage in the CNS are presumably involved in the
development of fatigue and chronic pain conditions
in various diseases.35 Side effects of medication
could also contribute to fatigue in pain patients.
We show that pain intensity in all patient groups
correlated with physical and mental impairment of
the patient’s hr-QoL. In contrast, the EDSS did not
differ between patients with and without pain. Pain
Asseyer et al.
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is not represented in the EDSS and therefore needs
to be carefully examined using patient medical his-
tory and specific evaluation tools.
In line with previous NMOSD studies,7 we show that
MOG-IgG-pos. NMOSD patients with pain are cur-
rently not effectively treated. Less than 40% of
patients with pain in both diagnostic categories
receive pain treatment, and even those were not
pain free. Pain intensity, impairment of general
health, and fatigue were even more severe in patients
with pain treatment than in patients without. These
findings might indicate that patients who complain
about severe pain are more likely to receive pain
medication than those who suffer from light pain;
however, it seems that pain treatment is not effective
in improving the patients’ QoL.
These alarming results show the necessity of
exploring the efficacy of a multimodal and multi-
disciplinary approach to pain management in
MOG-IgG-pos. NMOSD as well as in AQP4-IgG-
pos. and AQP4/MOG-IgG-neg. NMOSD since
pharmacologic interventions are currently insufficient.
Limitations
Results from single-center studies are not generaliz-
able to a broader population, especially since sample
sizes are small. Nonetheless, the overlap of our
results in NMOSD patients with previously pub-
lished data supports validity in a broader context.
Patients who tested AQP4-IgG and MOG-IgG neg-
ative might show antibody positivity if tests were
more sensitive, but fulfill the current criteria for
antibody-negative NMOSD. Because of the small
number of AQP4/MOG-IgG-neg. NMOSD patients,
we used descriptive data only and did not include
them in statistical comparisons. Finally, our results
do not allow any certain pathophysiologi-
cal conclusion.
Conclusions
Pain is a frequent and severe symptom of patients
suffering from MOG-IgG-pos., AQP4-IgG-pos. and
AQP4/MOG-IgG-neg. NMOSD. The vast majority
of MOG-IgG-pos. and AQP4-IgG-pos. NMOSD
patients suffer from pain. MOG-IgG-pos. NMOSD
patients suffer from headache or neuropathic pain,
whereas AQP4-IgG-pos. NMOSD patients mostly
suffer from neuropathic pain. These findings might
be linked to different underlying pathophysiological
mechanisms in AQP4-IgG-pos. NMOSD patients,
causative for neuropathic pain. Both patient groups
describe their pain experience differently, while its
impact on the patients’ QoL is similar. Pain is cur-
rently insufficiently controlled by medication. Only
between one-third and one-half of patients receive
pain medication and among those, not one is perma-
nently free of pain. Therefore, it is important to sys-
tematically record pain, to carefully distinguish
among different pain types, and to concentrate in
future research on effective pain management in
patients suffering from NMOSD.
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